COMP <GO>
PCRX vs ANAB // EV/EBITDA & P/E VALUATION
Pacira BioSciences Inc. (NASDAQ) VS. AnaptysBio Inc. (NASDAQ) • 15-METRIC TALLY: PCRX 5
— ANAB 4
▲ EV/EBITDA & P/E VALUATION LEADER: ANAB
LAST: $36.39 (0.00%) • MKT CAP: $1.45B
valuation
51.6x
LAST: $48.64 (-3.68%) • MKT CAP: $1.44B
valuation
5.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCRX VS. ANAB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCRX | ANAB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.70% | 85.00% | -83.30 | ANAB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 51.6x | 5.7x | +45.90 | ANAB | /valuation <GO> |
| Free Cash Flow Yield | 9.42% | 1.36% | +8.06 | PCRX | /fcf-yield <GO> |
| Operating Margin | 2.60% | 75.00% | -72.40 | ANAB | /operating-margins <GO> |
| Net Profit Margin | 1.00% | -5.60% | +6.60 | PCRX | /net-margins <GO> |
| Revenue Growth (YoY) | 3.60% | 157.00% | -153.40 | ANAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.33 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PCRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 83.2 | 46.7 | +36.48 | PCRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.45B | $1.44B | $10.4M | PCRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCRX REV | ANAB REV | PCRX GROSS % | ANAB GROSS % | PCRX FCF | ANAB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $726.4M | $234.6M | 79.4% | — | $136.7M | $19.6M |
| FY 2024 | $701.0M | $91.3M | 75.7% | — | $178.8M | -$135.7M |
| FY 2023 | $675.0M | $17.2M | — | — | $154.6M | -$120.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCRX // BETA —
ANAB // BETA —